Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.60 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.60 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171835 | 0.97 | — | — | |
| SCHEMBL2243521 | 0.95 | GABBR2 (0.60) | GABBR2GABBR1GABRR1PPARDLPAR3 | |
| SCHEMBL11429786 | 0.84 | GABBR2 (0.71) | GABBR2GABBR1GABRR1LPAR3LPAR2 | |
| SCHEMBL4772201 | 0.82 | GABBR2 (0.62) | GABBR2GABBR1GABRR1LPAR3LPAR2 | |
| SCHEMBL28885310 | 0.82 | GABBR2 (0.62) | GABBR2GABBR1GABRR1LPAR3LPAR2 | |
| SCHEMBL1359225 | 0.81 | — | — | |
| SCHEMBL11593686 | 0.81 | GABBR2 (0.68) | GABBR2GABBR1GABRR1LPAR3LPAR2 | |
| 1,4-Butanediol SCHEMBL5492109 | 0.81 | GABBR2 (0.48) | GABBR2GABBR1GABRR1PPARDLPAR3 | |
| 1,3-Propanediol SCHEMBL5491466 | 0.81 | GABBR2 (0.48) | GABBR2GABBR1GABRR1PPARDLPAR3 | |
| SCHEMBL25387715 | 0.80 | GABBR2 (0.60) | GABBR2GABBR1GABRR1LPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604108-B2 | Method for producing mono-hydroxyfunctionalized dialkylphosphinic acids and esters and salts thereof by means of acroleins and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-12-10 | — | — | US | disclosed |
| US-20110224339-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Acroleins and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224339-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Acroleins and Use Thereof | HAO2, AOC3, AOC2 | GABBR2 2979/4885GABBR1 3462/4885GABRR1 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.